SCHEMBL3357413

SCHEMBL3357413

c1cnn2cc(-c3ccnnc3)nc2c1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 6/20 0.36
RAB9A P51151 6/20 0.36
MEN1 O00255 2/20 0.36
KMT2A Q03164 2/20 0.36
SMN1; SMN2 Q16637 2/20 0.36
PDE10A Q9Y233 1/20 0.35
MKNK1 Q9BUB5 1/20 0.35
DYRK1A Q13627 1/20 0.33
PDE4B Q07343 3/20 0.33
PDE4D Q08499 2/20 0.33
RBP4 P02753 1/20 0.33
MAPT P10636 3/20 0.32
TP53 P04637 2/20 0.32
GSK3A P49840 1/20 0.32
GSK3B P49841 1/20 0.32
KDM4E B2RXH2 4/20 0.32
ALDH1A1 P00352 2/20 0.32
USP2 O75604 1/20 0.32
TDP1 Q9NUW8 1/20 0.32
L3MBTL1 Q9Y468 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1202800 0.79 ALDH1A1 (0.49) NPC1RAB9AMEN1KMT2ASMN1; SMN2
SCHEMBL3356308 0.76 PDE10A (0.38) NPC1RAB9AMEN1KMT2ASMN1; SMN2
SCHEMBL10756399 0.75 RAB9A (0.46) NPC1RAB9AMEN1KMT2ASMN1; SMN2
SCHEMBL12970200 0.75 RAB9A (0.55) NPC1RAB9AMEN1KMT2ASMN1; SMN2
SCHEMBL5309811 0.75 NPC1 (0.57) NPC1RAB9AMEN1KMT2ASMN1; SMN2
SCHEMBL15473569 0.75 NPC1 (0.57) NPC1RAB9APDE10AMAPTTP53
Hydrochloric Acid SCHEMBL30669775 0.74 JAK2 (0.45) MAPT
SCHEMBL19305218 0.73 DYRK1A (0.40) NPC1RAB9AMEN1KMT2ASMN1; SMN2
SCHEMBL15473615 0.72 GRM5 (0.39) NPC1RAB9APDE10ADYRK1APDE4B
SCHEMBL10754174 0.72 CA2 (0.51) NPC1RAB9ASMN1; SMN2KDM4EALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9108971-B2 6-cycloamino-3-(pyridazin-4-yl)imidazo[1,2-b]-pyridazine and derivatives thereof preparation and therapeutic application thereof SANOFI (FR) 2015-08-18 US disclosed
US-20130245023-A1 6-CYCLOAMINO-3-(PYRIDAZIN-4-YL)IMIDAZO[1,2-b]-PYRIDAZINE AND DERIVATIVES THEREOF PREPARATION AND THERAPEUTIC APPLICATION THEREOF SANOFI (FR) 2013-09-19 US disclosed
EP-2178879-B1 6-CYCLOAMINO-S-(PYRIDAZIN-4-YL)IMIDAZO[1,2-B]-PYRIDAZINE AND DERIVATIVES THEREOF PREPARATION AND THERAPEUTIC APPLICATION THEREOF SANOFI SA (FR) 2013-07-03 EP disclosed
US-8455491-B2 6-cycloamino-3-(pyridazin-4-yl)imidazo[1,2-b]pyridazine and derivatives and pharmaceutical compositions comprising the same SANOFI (FR) 2013-06-04 US disclosed
US-20100152157-A1 6-CYCLOAMINO-3-(PYRIDAZIN-4-YL)IMIDAZO[1,2-b]-PYRIDAZINE AND DERIVATIVES THEREOF PREPARATION AND THERAPEUTIC APPLICATION THEREOF SANOFI-AVENTIS (FR) 2010-06-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130245023-A1 6-CYCLOAMINO-3-(PYRIDAZIN-4-YL)IMIDAZO[1,2-b]-PYRIDAZINE AND DERIVATIVES THEREOF PREPARATION AND THERAPEUTIC APPLICATION THEREOF TLR7, IFNAR1, CBR3 NPC1 3017/4885RAB9A 1762/4885MEN1 3211/4885
US-20100152157-A1 6-CYCLOAMINO-3-(PYRIDAZIN-4-YL)IMIDAZO[1,2-b]-PYRIDAZINE AND DERIVATIVES THEREOF PREPARATION AND THERAPEUTIC APPLICATION THEREOF IFNAR1, TLR7, CBR3 NPC1 3082/4885RAB9A 1802/4885MEN1 3233/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.